Enzalutamide
Anti-Androgens
Sold as XTANDI
- Drug class
- Anti-Androgens
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 38
Overview
Enzalutamide is an active pharmaceutical ingredient in the Anti-Androgens group (L02BB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 30 | May 29, 2026 |
| CA Canada | Health Canada | 5 | May 20, 2026 |
| EU European Union | EMA | 3 | March 26, 2026 |
GBUnited Kingdom· MHRA
30 products
Uses
1). 1). 1). 1). • for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.
How to take
CACanada· Health Canada
5 products
Uses
Xtandi® (enzalutamide) is indicated for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR) (see 14 CLINICAL TRIALS). Xtandi® (enzalutamide) is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Xtandi® (enzalutamide) is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Xtandi has not been studied in patients with nmCRPC at low risk of developing metastatic disease (see 14 CLINICAL TRIALS).
The benefit and risk profile in these patients is unknown. Xtandi® (enzalutamide) is indicated in the setting of medical or surgical castration for the treatment of metastatic castration-resistant prostate cancer (CRPC) in patients who: • are chemotherapy-naïve with asymptomatic or mildly symptomatic disease after failure of androgen deprivation therapy.
EUEuropean Union· EMA
3 products
Uses
1). 1). 1). 1). • for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.
How to take
Drug interactions
Known interactions involving Enzalutamide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 546. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL044161742 · revised March 13, 2026
- [2]Health Canada (DPD) · 02407329 · revised February 26, 2026
- [3]European Medicines Agency · EMEA/H/C/002639 · revised March 26, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.